<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medical  Diagnosis</journal-title></journal-title-group><issn pub-type="epub">2164-540X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/MD.2016.63014</article-id><article-id pub-id-type="publisher-id">MD-18671</article-id><article-categories><subj-group subj-group-type="heading"><subject>MD20160300000_12323380.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  症状性脑血管痉挛的动脉内法舒地尔治疗
  Intra-Arterial Infusion of Fasudil as a Treatment of Symptomatic Vasospasm Following SAH
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潘</surname><given-names>源</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>卢</surname><given-names>立军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>高明</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>韩</surname><given-names>冲</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>贺</surname><given-names>西亮</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>辛</surname><given-names>涛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>92330部队后勤部医院，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>解放军第401医院神经外科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>xtdlcc@hotmail.com(辛涛)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>09</month><year>2016</year></pub-date><volume>06</volume><issue>03</issue><fpage>79</fpage><lpage>83</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：评价盐酸法舒地尔选择性脑动脉内滴注，治疗蛛网膜下腔出血后症状性脑血管痉挛的即时影像学改变和临床疗效。方法：回顾性分析动脉瘤性蛛网膜下腔出血后出现症状性脑血管痉挛的20例患者，介入手术治疗后常规给予“3H”治疗 + 尼莫地平治疗，出现症状性脑血管痉挛后予以造影评估并动脉内法舒地尔滴注治疗，观察治疗前后影像学及症状变化，治疗前后进行NIHSS评分，并随访3个月后行GOS评分，评价远期疗效。结果：NIHSS评分在法舒地尔治疗前后有显著差异(P = 0.03)；法舒地尔动脉内滴注后23例次造影图像均有改善(100%)，完全缓解19例次(74%)；3个月随访，恢复良好比例占85%；法舒地尔滴注治疗中无一例患者出现严重并发症。结论：法舒地尔动脉内滴注治疗，对蛛网膜下腔出血后症状性脑血管痉挛患者有较好的临床疗效及远期预后，控制法舒地尔剂量和给药速率，治疗安全，疗效可靠。
   Objective: We investigated the clinical efficacy and safety of intra-arterial administration of fasudil hydrochloride for symptomatic cerebral vasospasm. Methods: 20 cases of symptomatic cerebral vasospasm following subarachnoid hemorrhage (SAH) were retrospectively analyzed. All cases received “3H” + nimodopine therapy and intra-arterial fasudil treatment when the sympomatic vasospasm occurs. Comparison of clinical data between per- and post-therapy and the Glasgow Outcome Scale (GOS) after 3 months were done by statistical analysis. Results: The study showed angiographic improvement in all occasions and better NIHSS scale of per- and post-therapy (P = 0.03). The complete dilation of vasospasm was achieved in 19 occasions (74%). At 3-month fol-low-up, 85% patients showed good recovery on GOS. None severe complications occurred during the fasudil administration. Conclusion: The intra-arterial administration of fasudil therapy was effective for patients with symptomatic vasospasm after subarachnoid hemorrhage. When using a suitable dosage and velocity, the treatment was safe and reliable.
 
</p></abstract><kwd-group><kwd>法舒地尔，蛛网膜下腔出血，症状性脑血管痉挛, Fasudil</kwd><kwd> Subarachnoid Hemorrhage</kwd><kwd> Symptomatic Cerebral Vasospasm</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>症状性脑血管痉挛的动脉内法舒地尔治疗<sup> </sup></title><p>潘源<sup>1</sup>，卢立军<sup>1</sup>，陈高明<sup>2</sup>，韩冲<sup>2</sup>，贺西亮<sup>1</sup>，辛涛<sup>1*</sup></p><p><sup>1</sup>解放军第401医院神经外科，山东 青岛</p><p><sup>2</sup> 92330部队后勤部医院，山东 青岛</p><disp-formula id="hanspub.18671-formula231"><graphic xlink:href="http://html.hanspub.org/file/4-2170135x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2016年9月8日；录用日期：2016年9月24日；发布日期：2016年9月30日</p><disp-formula id="hanspub.18671-formula232"><graphic xlink:href="http://html.hanspub.org/file/4-2170135x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：评价盐酸法舒地尔选择性脑动脉内滴注，治疗蛛网膜下腔出血后症状性脑血管痉挛的即时影像学改变和临床疗效。方法：回顾性分析动脉瘤性蛛网膜下腔出血后出现症状性脑血管痉挛的20例患者，介入手术治疗后常规给予“3H”治疗 + 尼莫地平治疗，出现症状性脑血管痉挛后予以造影评估并动脉内法舒地尔滴注治疗，观察治疗前后影像学及症状变化，治疗前后进行NIHSS评分，并随访3个月后行GOS评分，评价远期疗效。结果：NIHSS评分在法舒地尔治疗前后有显著差异(P = 0.03)；法舒地尔动脉内滴注后23例次造影图像均有改善(100%)，完全缓解19例次(74%)；3个月随访，恢复良好比例占85%；法舒地尔滴注治疗中无一例患者出现严重并发症。结论：法舒地尔动脉内滴注治疗，对蛛网膜下腔出血后症状性脑血管痉挛患者有较好的临床疗效及远期预后，控制法舒地尔剂量和给药速率，治疗安全，疗效可靠。</p><p>关键词 :法舒地尔，蛛网膜下腔出血，症状性脑血管痉挛</p><disp-formula id="hanspub.18671-formula233"><graphic xlink:href="http://html.hanspub.org/file/4-2170135x9_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>脑血管痉挛是动脉瘤性蛛网膜下腔出血(SAH)后常见的病理过程，引起脑缺血症状甚至严重的神经功能障碍，仍是患者致死、致残的主要原因 [<xref ref-type="bibr" rid="hanspub.18671-ref1">1</xref>] 。脑血管痉挛的发生涉及内皮损伤、平滑肌细胞收缩、炎症反应等数个病理过程，基础研究和临床治疗一直是研究的热点。Rho激酶是多种血管疾病的靶点，Rho激酶活性增加可导致血管平滑肌细胞收缩，而法舒地尔是Rho激酶抑制剂，文献报道能有效预防和治疗脑血管痉挛，动脉内滴注盐酸法舒地尔治疗症状性脑血管痉挛在国外有少数研究报道，本文回顾性分析我院2013.05~2016.03期间20例症状性脑血管痉挛后行法舒地尔超选择性脑动脉内滴注治疗的患者，评估治疗前后的影像学改变和临床疗效。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>本研究所有病例为2013.05~2016.03期间在我院神经外科住院的动脉瘤破裂介入手术治疗后出现症状性脑血管痉挛的患者，发病后24小时内接受介入手术治疗，20岁~75岁，排除Hunt-Hess5级濒死患者，同时排除血管痉挛以外的原因，如再出血、电解质失衡、脑积水等病因。</p></sec><sec id="s4_2"><title>2.2. 研究方法</title><p>所有患者术后常规“3H (hypertension, hypervolemia, hemodilution)”治疗，常规尼莫地平注射液，微量泵泵入，4 mg/H，连续14天；每日腰椎穿刺释放血性脑脊液；出现症状性血管痉挛后行DSA评估，并行动脉内法舒地尔治疗，法舒地尔30 mg + 0.9%氯化钠注射液250 ml，加压袋加压滴注，控制滴速，120滴/分，约30分钟缓慢滴注，每3分钟测量血压变化，注意患者意识、头痛、肢体抽搐、面部潮红等变化，滴注结束行造影复查，可重复滴注1~2次；根据患者病情住院期间可多次实施上述治疗。</p></sec><sec id="s4_3"><title>2.3. 观察指标</title><sec id="s4_3_1"><title>2.3.1. 造影评估</title><p>以入院手术时的血管直径作为参考，治疗前后均造影评估血管痉挛程度。为减少误差，主要关注颈内动脉C1~C3段，大脑前动脉A1段，大脑中动脉M1段。根据动脉直径收缩程度分为轻度 &lt; 25%；中度25%~50%；重度 &gt; 50%。治疗后管径恢复正常定义为完全缓解，血管部分反应定义不完全缓解 [<xref ref-type="bibr" rid="hanspub.18671-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.18671-ref3">3</xref>] 。</p></sec><sec id="s4_3_2"><title>2.3.2. 即时临床疗效评估</title><p>治疗前及24小时后进行神经功能评估，以NIHSS评分为指标。</p></sec><sec id="s4_3_3"><title>2.3.3. 预后评估</title><p>所有患者出院后随访3个月，行GOS 5级评分 [<xref ref-type="bibr" rid="hanspub.18671-ref4">4</xref>] ，以评估药物的远期疗效。</p></sec></sec><sec id="s4_4"><title>2.4. 统计方法</title><p>统计学处理应用SPSS13.0软件，P &lt; 0.05为存在显著性差异。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 患者一般资料(见表1)</title><p>患者平均年龄59.10 &#177; 8.83岁；女16例，男4例，前循环动脉瘤共有17例，后循环动脉瘤3例。有2例患者进行了多次法舒地尔治疗，1例Hunt-Hess 3级患者术后第4天、第5天分别进行法舒地尔治疗；1例Hunt-Hess 4级患者，因意识水平下降，在术后第3天、第4天、第6天分别进行法舒地尔治疗。</p></sec><sec id="s5_2"><title>3.2. 造影改善</title><p>20例患者共进行了23例次的DSA评估和法舒地尔治疗，根据痉挛血管的分布，8例次造影导管位于颈总动脉进行非选择性法舒地尔滴注，15例次局限性血管痉挛进行选择性A1、M1滴注治疗；造影图像均有改善，完全缓解19例次，74% (19/23)，不完全缓解4例次，26% (4/23)。</p></sec><sec id="s5_3"><title>3.3. 症状改善</title><p>法舒地尔治疗后临床症状改善主要表现在意识水平好转，肢体肌力好转，治疗后多数患者临床症状明显改善，NIHSS评分在术后均有下降，治疗前后轻、中、重度分布有差异，P &lt; 0.05；治疗过程中，严密观察生命体征变化，未出现抽搐、严重低血压、头痛、面部潮红等副作用。</p></sec><sec id="s5_4"><title>3.4. 随访</title><p>远期疗效以3个月时GOS评分为标准。恢复良好比例占85% (17/20)；未出现植物生存及死亡患者。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>动脉瘤性蛛网膜下腔出血(SAH)后27%左右的患者会出现症状性脑血管痉挛(SVS)，其病理机制尚不完全清楚 [<xref ref-type="bibr" rid="hanspub.18671-ref5">5</xref>] ，涉及平滑肌细胞收缩、内皮损伤、血管反应性变化、炎症反应等多个病理过程，进展性的血管狭窄造成脑缺血症状，仍是SAH后残疾和死亡的主要原因 [<xref ref-type="bibr" rid="hanspub.18671-ref6">6</xref>] 。目前脑血管痉挛的主要治疗包括预防性应用血管扩张药物、腔内血管成型术、“3H”治疗(hypertension, hypervolemia, hemodilution)等，到目</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> General data of patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >病例组</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >例数(女/男)</td><td align="center" valign="middle" >16/4</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >年龄(mean &#177; SD，岁)</td><td align="center" valign="middle" >59.10 &#177; 8.83</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >动脉瘤位置(例数，%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >前交通</td><td align="center" valign="middle" >3 (15%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >后交通</td><td align="center" valign="middle" >8 (40%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >大脑中</td><td align="center" valign="middle" >4 (20%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >大脑前</td><td align="center" valign="middle" >2 (10%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >后循环</td><td align="center" valign="middle" >3 (15%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Hunt-Hess分级(例数，%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >1级</td><td align="center" valign="middle" >2 (10%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >2级</td><td align="center" valign="middle" >6 (30%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >3级</td><td align="center" valign="middle" >10 (50%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >4级</td><td align="center" valign="middle" >2 (10%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >GOS评分(例数，%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >恢复良好</td><td align="center" valign="middle" >17 (85%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >轻度残疾</td><td align="center" valign="middle" >2 (10%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >严重残疾</td><td align="center" valign="middle" >1 (5%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >植物状态</td><td align="center" valign="middle" >0 (0%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >死亡</td><td align="center" valign="middle" >0 (0%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >NIHSS分布(治疗前→后例数)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.03</td></tr><tr><td align="center" valign="middle" >轻度</td><td align="center" valign="middle" >8例→16例</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >中度</td><td align="center" valign="middle" >10例→4例</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >重度</td><td align="center" valign="middle" >2例→0例</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 患者一般资料</p><p>前为止，预防性的尼莫地平治疗和“3H”治疗仍被广泛认可，其他药物治疗，包括镁剂、他汀类、内皮素受体拮抗剂、自由基清除剂、血栓素抑制剂、溶栓剂、抗炎药物和神经保护剂等仍没有统一的结论。盐酸法舒地尔是一种新型的有效的血管扩张剂 [<xref ref-type="bibr" rid="hanspub.18671-ref7">7</xref>] ，通过抑制肌球蛋白轻链磷酸酯酶而抑制血管平滑肌收缩 [<xref ref-type="bibr" rid="hanspub.18671-ref8">8</xref>] ，能预防血流动力学障碍，参与调节炎症过程，其代谢产物也有解痉活性，用药后维持约8小时 [<xref ref-type="bibr" rid="hanspub.18671-ref9">9</xref>] 。国外已经有多个研究采用选择性脑动脉内滴注法舒地尔治疗脑血管痉挛 [<xref ref-type="bibr" rid="hanspub.18671-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.18671-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.18671-ref11">11</xref>] ，国内尚无此类研究报道。</p><p>动脉内应用法舒地尔最主要的副作用是颅内出血和低血压 [<xref ref-type="bibr" rid="hanspub.18671-ref12">12</xref>] ，个别患者出现头痛、发热症状，目前关于动脉内法舒地尔治疗的合理剂量和滴注速度尚没有统一标准，文献中用量15~60 mg [<xref ref-type="bibr" rid="hanspub.18671-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.18671-ref13">13</xref>] ，在本组病例中，应用法舒地尔时严密监测患者生命体征变化，实时心电监护，每3分钟测量血压水平，我们总结的方法是法舒地尔30 mg + 0.9%氯化钠注射液250 ml，加压袋加压滴注，控制滴速，120滴/分，约30分钟缓慢滴注，无一例患者出现抽搐、颅内出血及严重低血压(血压下降超过20 mmHg)。随访时恢复良好比例占85%，其余15%病人症状无显著持续改善，主要为NIHSS分值过高者，考虑原因并非单纯由脑血管痉挛所致，无因应用该药物出现后续不良反应病例。</p><p>法舒地尔动脉内滴注治疗能有效的缓解症状性脑血管痉挛，治疗前后影像学有明显改善，以NIHSS评分为依据的神经功能有明显改善，改善临床预后，严格控制剂量和速率，是安全、有效的。本研究是回顾性的，样本小，尚需要更大病例数样本，以及前瞻性临床随机对照研究，以评估动脉内法舒地尔治疗脑血管痉挛的疗效和安全性。</p></sec><sec id="s7"><title>基金项目</title><p>青岛市民生计划项目(2014-WJZD191)；青岛市卫生局计划项目(13-1-3-52-nsh)。</p></sec><sec id="s8"><title>文章引用</title><p>潘源,卢立军,陈高明,韩冲,贺西亮,辛涛. 症状性脑血管痉挛的动脉内法舒地尔治疗 Intra-Arterial Infusion of Fasudil as a Treatment of Symptomatic Vasospasm Following SAH[J]. 医学诊断, 2016, 06(03): 79-83. http://dx.doi.org/10.12677/MD.2016.63014</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.18671-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Adamczyk, P., He, S., Amar, A.P., et al. (2013) Medical Management of Cerebral Vasospasm following Aneurysmal Subarachnoid Hemorrhage: A Review of Current and Emerging Therapeutic Interventions. Neurology Research International, 2013, 462-491. &lt;br&gt;http://dx.doi.org/10.1155/2013/462491</mixed-citation></ref><ref id="hanspub.18671-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Biondi, A., Ricciardi, G.K., Puybasset, L., et al. (2004) Intra-Arterial Nimodipine for the Treatment of Symptomatic Cerebral Vasospasm after Aneurysmal Subarachnoid Hemorrhage: Preliminary Results. American Journal of Neuroradiology, 2, 1067-1076.</mixed-citation></ref><ref id="hanspub.18671-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Clouston, J.E., Numaguchi, Y., Zoarski, G.H., et al. (1995) Intraarterial Papaverine Infusion for Cerebral Vasospasm after Subarachnoid Hemorrhage. American Journal of Neuroradiology, 16, 27-38.</mixed-citation></ref><ref id="hanspub.18671-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Jennett, B. and Bond, M. (1975) Assessment of Outcome after Severe Brain Damage. Lancet, 1, 480-484.  
&lt;br&gt;http://dx.doi.org/10.1016/S0140-6736(75)92830-5</mixed-citation></ref><ref id="hanspub.18671-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Nakamura, T., Matsui, T., Hosono, A., et al. (2013) Beneficial Effect of Selective Intra-Arterial Infusion of Fasudil Hydrochloride as a Treatment of Symptomatic Vasospasm Following SAH. Acta Neuro-chirurgica Supplement, 115, 81-85. &lt;br&gt;http://dx.doi.org/10.1007/978-3-7091-1192-5_18</mixed-citation></ref><ref id="hanspub.18671-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tanaka, K., Minami, H., Kota, M., et al. (2005) Treatment of Cerebral Vasospasm with Intra-Arterial Fasudil Hydrochloride. Neurosurgery, 56, 214-223. &lt;br&gt;http://dx.doi.org/10.1227/01.NEU.0000147975.24556.BC</mixed-citation></ref><ref id="hanspub.18671-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Shibuya, M., Asano, T. and Sasaki, Y. (2001) Effect of Fasudil HCl, a Protein Kinase Inhibitor, on Cerebral Vasospasm. Acta Neurochirurgica Supplement, 77, 201-204. &lt;br&gt;http://dx.doi.org/10.1007/978-3-7091-6232-3_42</mixed-citation></ref><ref id="hanspub.18671-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Iwabuchi, S., Yokouchi, T., Hayashi, M., et al. (2011) Intra-Arterial Administration of Fasudil Hydrochloride for Vasospasm Following Subarachnoid Haemorrhage: Experience of 90 Cases. Acta Neu-rochirurgica Supplement, 110, 179- 181.</mixed-citation></ref><ref id="hanspub.18671-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Masaoka, H., Takasato, Y., Nojiri, T., et al. (2001) Clinical Effect of Fasudil Hy-drochloride for Cerebral Vasospasm Following Subarachnoid Hemorrhage. Acta Neurochirurgica Supplement, 77, 209-211.  
&lt;br&gt;http://dx.doi.org/10.1007/978-3-7091-6232-3_44</mixed-citation></ref><ref id="hanspub.18671-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Iwabuchi, S., Hayashi, M., Yokouchi, T., et al. (2015) Prophylactic In-tra-Arterial Administration of Fasudil Hydrochloride for Vasospasm Following Subarachnoid Haemorrhage. Acta Neurochirurgica Supplement, 120, 167-169.</mixed-citation></ref><ref id="hanspub.18671-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Satoh, S.I., Ikegaki, I., Kawasaki, K., et al. (2014) Pleiotropic Effects of the Rho-Kinase Inhibitor Fasudil after Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies. Current Vascular Pharmacology, 12, 758-765.  
&lt;br&gt;http://dx.doi.org/10.2174/1570161112666140613115813</mixed-citation></ref><ref id="hanspub.18671-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Enomoto, Y., Yoshimura, S., Yamada, K., et al. (2010) Convul-sion during Intra-Arterial Infusion of Fasudil Hydrochloride for the Treatment of Cerebral Vasospasm Following Subarachnoid He-morrhage. Neurologia Medico-Chirurgica (Tokyo), 50, 7-12. &lt;br&gt;http://dx.doi.org/10.2176/nmc.50.7</mixed-citation></ref><ref id="hanspub.18671-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Tachibana, E., Harada, T., Shibuya, M., et al. (1999) Intra-Arterial Infusion of Fasudil Hydrochloride for Treating Vasospasm Following Subarachnoid Hae-morrhage. Acta Neurochirurgica (Wien), 141, 13-19.  
&lt;br&gt;http://dx.doi.org/10.1007/s007010050260</mixed-citation></ref></ref-list></back></article>